Recently published data showed that repeated subcutaneous administration of very low dose rflagellin (e.g, 2 μg/mouse) in allo-BMT recipients enhanced anti-tumor immunity of CD8+ T cells without increasing GvHD toxicity [46]. The gene discussed is CD8A; the disease is graft versus host disease.